Peak Financial Advisors LLC acquired a new stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund acquired 41,880 shares of the company's stock, valued at approximately $472,000.
Other institutional investors and hedge funds have also bought and sold shares of the company. Parallel Advisors LLC lifted its stake in Roivant Sciences by 80.5% during the 1st quarter. Parallel Advisors LLC now owns 2,485 shares of the company's stock valued at $25,000 after acquiring an additional 1,108 shares during the period. UMB Bank n.a. lifted its stake in Roivant Sciences by 112.7% during the 1st quarter. UMB Bank n.a. now owns 4,143 shares of the company's stock valued at $42,000 after acquiring an additional 2,195 shares during the period. Russell Investments Group Ltd. lifted its stake in Roivant Sciences by 94.8% during the 1st quarter. Russell Investments Group Ltd. now owns 4,588 shares of the company's stock valued at $46,000 after acquiring an additional 2,233 shares during the period. Fifth Third Bancorp lifted its stake in Roivant Sciences by 59.3% during the 1st quarter. Fifth Third Bancorp now owns 5,118 shares of the company's stock valued at $52,000 after acquiring an additional 1,905 shares during the period. Finally, GAMMA Investing LLC lifted its stake in Roivant Sciences by 83.0% during the 1st quarter. GAMMA Investing LLC now owns 6,493 shares of the company's stock valued at $66,000 after acquiring an additional 2,945 shares during the period. 64.76% of the stock is currently owned by institutional investors and hedge funds.
Roivant Sciences Price Performance
ROIV opened at $14.08 on Friday. The firm has a fifty day moving average price of $11.86 and a 200 day moving average price of $11.14. Roivant Sciences Ltd. has a 1 year low of $8.73 and a 1 year high of $14.48. The stock has a market cap of $9.61 billion, a P/E ratio of -20.11 and a beta of 1.15.
Analyst Upgrades and Downgrades
Several analysts have commented on the stock. Citigroup assumed coverage on shares of Roivant Sciences in a research note on Tuesday, September 2nd. They set a "buy" rating and a $16.00 price objective for the company. The Goldman Sachs Group upgraded shares of Roivant Sciences to a "strong-buy" rating and set a $19.00 price objective for the company in a research note on Thursday, July 10th. Finally, HC Wainwright reiterated a "buy" rating and issued a $18.00 target price on shares of Roivant Sciences in a research note on Wednesday, June 18th. Two research analysts have rated the stock with a Strong Buy rating and two have given a Buy rating to the stock. According to data from MarketBeat.com, Roivant Sciences presently has a consensus rating of "Strong Buy" and a consensus target price of $17.67.
Check Out Our Latest Analysis on ROIV
Insider Buying and Selling at Roivant Sciences
In other Roivant Sciences news, CEO Eric Venker sold 100,000 shares of the company's stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $11.72, for a total transaction of $1,172,000.00. Following the completion of the transaction, the chief executive officer directly owned 1,653,585 shares in the company, valued at approximately $19,380,016.20. This represents a 5.70% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Vivek Ramaswamy sold 1,195,000 shares of the company's stock in a transaction on Wednesday, September 3rd. The stock was sold at an average price of $12.50, for a total transaction of $14,937,500.00. Following the transaction, the insider owned 36,089,108 shares of the company's stock, valued at $451,113,850. This represents a 3.21% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 3,218,022 shares of company stock valued at $39,010,006. Company insiders own 10.80% of the company's stock.
Roivant Sciences Profile
(
Free Report)
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Roivant Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list.
While Roivant Sciences currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
